Bringing next generation single-use sensor technologies to the life science market
Pall and Broadley-James’ combined expertise proves complementary in addressing critical customer pain points in modern bioprocessing.
Pall Corporation has partnered with Broadley-James Corporation to integrate and distribute Broadley-James’ advanced single-use probe and flow cell pH sensors. With applications across upstream and downstream unit operations, the sensor will be integrated into Pall Biotech’s single-use (SU) technologies, as well as other commercially available bioprocessing platforms.
“Pall’s single-use bioprocessing know-how and Broadley-James’ expertise in sensor development have proven complementary in addressing critical customer pain points in modern bioprocessing,” explained Martin Smith, Chief Technology Officer of Pall Corporation. “In particular, the new single-use pH sensor solution allows us to offer customers the robustness of traditional sensor technologies integrated into their single-use systems.”
The novel SU pH sensors leverage widely accepted glass electrochemical technology, the only method that meets international standards for pH measurement. The design includes a calibrated buffer storage environment for the sensor to eliminate previous constraints during pre-integration of glass pH sensors into consumables. Users will be able to operate in closed systems, without sacrificing performance.
“Customers currently rely on calibration data gathered before the sensor is sterilized, which can affect the measurement accuracy,” said Robert Garrahy, Vice-President at Broadley-James. “Our patent-pending new storage solutions design features a known pH buffer, enabling robust pre-use calibration. By pairing trusted technology with cutting-edge design, we are able to offer the best balance of risk reduction and performance.”
The Broadley-James single-use probe and flow cell pH sensors are currently in beta testing and when launched will be available exclusively through Pall Biotech. Parallel technical and process development support is also available to optimize use of this new technology.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...